RetroSearch Browse

Home - News ( United States | United Kingdom | Italy | Germany ) - Football scores

Showing content from https://pubmed.ncbi.nlm.nih.gov/27607465/ below:

Subsequent Breast Cancer Risk Following Diagnosis of Atypical Ductal Hyperplasia on Needle Biopsy

doi: 10.1001/jamaoncol.2016.3022. Subsequent Breast Cancer Risk Following Diagnosis of Atypical Ductal Hyperplasia on Needle Biopsy

Affiliations

¹ Department of Surgery, Tel Aviv-Sourasky Medical Center, Tel Aviv, Israel2Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
² Department of Medicine, University of California, San Francisco4Department of Epidemiology and Biostatistics, University of California, San Francisco.
³ Fred Hutchinson Cancer Research Center, Seattle, Washington.
⁴ Department of Pathology, Mount Sinai Medical Center, New York, New York.
⁵ Radiology Associates of Albuquerque, Albuquerque, New Mexico8Department of Radiology, University of New Mexico, Albuquerque.
⁶ Group Health Research Institute, Group Health Cooperative, Seattle, Washington10Division of Biostatistics, Department of Public Health Sciences, University of California Davis School of Medicine, Sacramento.

PMID: 27607465
PMCID: PMC5650059
DOI: 10.1001/jamaoncol.2016.3022

Item in Clipboard

Subsequent Breast Cancer Risk Following Diagnosis of Atypical Ductal Hyperplasia on Needle Biopsy

Tehillah S Menes et al. JAMA Oncol. 2017.

doi: 10.1001/jamaoncol.2016.3022. Affiliations

¹ Department of Surgery, Tel Aviv-Sourasky Medical Center, Tel Aviv, Israel2Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
² Department of Medicine, University of California, San Francisco4Department of Epidemiology and Biostatistics, University of California, San Francisco.
³ Fred Hutchinson Cancer Research Center, Seattle, Washington.
⁴ Department of Pathology, Mount Sinai Medical Center, New York, New York.
⁵ Radiology Associates of Albuquerque, Albuquerque, New Mexico8Department of Radiology, University of New Mexico, Albuquerque.
⁶ Group Health Research Institute, Group Health Cooperative, Seattle, Washington10Division of Biostatistics, Department of Public Health Sciences, University of California Davis School of Medicine, Sacramento.

PMID: 27607465
PMCID: PMC5650059
DOI: 10.1001/jamaoncol.2016.3022

Item in Clipboard

Abstract

Importance: Atypical ductal hyperplasia (ADH) is a known risk factor for breast cancer. Published risk estimates are based on cohorts that included women whose ADH was diagnosed before widespread use of screening mammograms and did not differentiate between the methods used to diagnose ADH, which may be related to the size of the ADH focus. These risks may overestimate the risk in women with presently diagnosed ADH.

Objective: To examine the risk of invasive cancer associated with ADH diagnosed using core needle biopsy vs excisional biopsy.

Design: A cohort study was conducted comparing the 10-year cumulative risk of invasive breast cancer in 955 331 women undergoing mammography with and without a diagnosis of ADH. Data were obtained from 5 breast imaging registries that participate in the National Cancer Institute-funded Breast Cancer Surveillance Consortium.

Exposures: Diagnosis of ADH on core needle biopsy or excisional biopsy in women undergoing mammography.

Main outcomes and measures: Ten-year cumulative risk of invasive breast cancer.

Results: The sample included 955 331 women with 1727 diagnoses of ADH, 1058 (61.3%) of which were diagnosed by core biopsy and 635 (36.8%) by excisional biopsy. The mean (interquartile range) age of the women at diagnosis was 52.6 (46.9-60.4) years. From 1996 to 2012, the proportion of ADH diagnosed by core needle biopsy increased from 21% to 77%. Ten years following a diagnosis of ADH, the cumulative risk of invasive breast cancer was 2.6 (95% CI, 2.0-3.4) times higher than the risk in women with no ADH. Atypical ductal hyperplasia diagnosed via excisional biopsy was associated with an adjusted hazard ratio (HR) of 3.0 (95% CI, 2-4.5) and, via core needle biopsy, with an adjusted HR of 2.2 (95% CI, 1.5-3.4). Ten years after an ADH diagnosis, an estimated 5.7% (95% CI, 4.3%-10.1%) of the women had a diagnosis of invasive cancer. Women with ADH diagnosed on excisional biopsy had a slightly higher risk (6.7%; 95% CI, 3.0%-12.8%) compared with those with ADH diagnosed via core needle biopsy (5%; 95% CI, 2.2%-8.9%).

Conclusions and relevance: Current 10-year risks of invasive breast cancer after a diagnosis of ADH may be lower than those previously reported. The risk associated with ADH is slightly lower for women whose ADH was diagnosed by needle core biopsy compared with excisional biopsy.

PubMed Disclaimer

Conflict of interest statement

Potential conflict of interest: None.

Figures
Figure 1

Rates of ADH per 10,000…

Figure 1

Rates of ADH per 10,000 screening mammograms (a); and mode of detection by…

Figure 1

Rates of ADH per 10,000 screening mammograms (a); and mode of detection by study year (b).